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Abstract: We have a limited arsenal with which to treat invasive fungal infections caused 
by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. 
A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug 
Administration and the European Medicines Agency for the treatment of invasive aspergillosis 
and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive 
aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study 
evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable 
response rates to amphotericin B and posaconazole treated historical controls. The prodrug 
isavuconazonium sulfate is commercially available in both an oral and intravenous formulation 
and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect 
profile, and favorable pharmacokinetics will likely solidify its place in therapy.
Keywords: isavuconazonium, antifungal, zygomycosis, mucor, mold infection, pharmacokinet-
ics, pharmacodynamics, clinical efficacy, therapy, new agent
Introduction
Invasive fungal infections are responsible for significant morbidity and mortality, 
 particularly in immunocompromised hosts. Although mortality from invasive  candidiasis 
has decreased in recent years, an overall increase in the number of deaths from invasive 
fungal infections has been noted, largely due to invasive aspergillosis and other molds.1–4 
The number of patients at risk has also increased as a greater number of patients are 
exposed to immunosuppressive therapy and more intensive chemotherapy regimens.
Currently available antifungal agents are useful for the management of the majority 
of the mycoses encountered in routine practice, however, significant differences exist 
between the triazoles in regard to efficacy, pharmacokinetics and pharmacodynamics, 
drug–drug interactions, the need for therapeutic drug monitoring (TDM), and  toxicity.5 
The use of amphotericin B is problematic given the incidence of nephrotoxicity and 
requirement for intravenous (IV) administration, and flucytosine is not useful as mono-
therapy for most infections and lacks meaningful activity against a multitude of others 
(including Aspergillus spp. and the Mucorales). The echinocandins are excellent agents 
in the fight against invasive candidal infections,6 however, their use in the treatment 
of aspergillosis is limited to combination or salvage therapy, and they are used solely 
in combination with polyenes in the treatment of mucormycosis.
The water-soluble prodrug isavuconazonium sulfate was developed specifically to 
facilitate IV administration without the need for potentially nephrotoxic  excipients such 
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as β-cyclodextrin, and displays excellent oral  bioavailability 
(∼98%).7 This review will summarize the role of this new 
triazole in the treatment of Aspergillus and Mucorales 
infections.
In vitro activity and animal models
The triazoles, including isavuconazole, exert their effects 
within the fungal cell membrane. The inhibition of cytochrome 
P450 (CYP)-dependent 14-α-demethylase by azoles prevents 
the conversion of lanosterol to ergosterol. This mechanism 
results in the accumulation of toxic methyl sterols and resultant 
inhibition of fungal cell growth and replication. The side arm 
of the active isavuconazole molecule allows for greater affinity 
of isavuconazole for the binding pocket in the fungal CYP51 
protein increasing the antifungal spectrum and conferring 
activity against some isolates resistant to other triazoles.8
The in vitro activity of isavuconazole has been demon-
strated against molds, yeasts, and dimorphic fungi using 
standardized methodologies as suggested by the Clinical and 
Laboratory Standards Institute.9–16 Activity is seen against 
most Aspergillus spp. including A. fumigatus, A. flavus, 
A. terreus, and A. niger16 with minimum inhibitory con-
centration to inhibit 50% of the organism growth (MIC
50
s) 
of 0.25–1 µg/mL. In recent years, the emergence of azole 
resistant Aspergillus spp. has become a threat to patients with 
the majority of clinical cases to date reported from western 
Europe.17 In these resistant isolates, mutations within the 
CYP51A gene (which encodes the enzyme targeted by azoles) 
or within the gene promoter, have been identified that reduce 
drug affinity or increase target quantity conferring azole resis-
tance. Aspergillus isolates with elevated minimal inhibitory 
concentrations (MICs) to posaconazole and voriconazole have 
been evaluated for isavuconazole susceptibility and cross-
resistance between azoles has been found inconsistent.18,19 
For example, Aspergillus isolates with the alterations L98, 
G138, Y431C, or G434C show elevated MICs to all triazoles 
including isavuconazole, however, the MICs of posaconazole 
are much lower than those of voriconazole and isavuconazole. 
In contrast, isolates with the G54 mutation show lower vori-
conazole and isavuconazole MICs compared to posaconazole, 
and MICs are variable among azoles in isolates with the M220 
alteration.18 These results suggest a potential role for routine 
susceptibility testing now that multiple azoles are available 
for clinical use. Further work will need to be performed to 
guide the clinician and to ensure these in vitro findings are 
indicative of in vivo efficacy.
Genera in the family Mucoraceae (order Mucorales) 
include Rhizopus, Cunninghamella, Lictheimia (formerly 
Absidia), Mucor, and Rhizomucor. Prior to the availability of 
isavuconazole, these organisms were resistant to all azoles 
with the exception of posaconazole.9 The in vitro activity 
of isavuconazole against the Mucorales is more variable 
with MIC
50
 values ranging from 1 to 4 µg/mL  depending 
on the specific species and isolate tested.20 For example, 
Rhizopus isolates have MIC values to isavuconazole as low 
as 0.12 µg/mL with others as high as 32 µg/mL; findings 
suggesting susceptibility testing should be performed on 
all Mucorales isolates in attempts to maximize pharma-
cokinetic/pharmacodynamic para meters during treatment.
Isavuconazole has fungistatic activity against yeasts 
such as Candida and Cryptococcus; however, appears to be 
fungicidal against Aspergillus spp. The area under the curve 
to MIC ratio (AUC/MIC) is the primary predictor of drug 
efficacy in animal models of aspergillosis.21–23 Animal models 
have thus far consisted primarily of dose-finding experiments 
given the differences in metabolism between murine models 
and humans, and assessments of efficacy using a number of 
different fungal species and strains. This work has thus far 
focused on Candida, Cryptococcus, Aspergillus, and the 
Mucorales, with other invasive molds, yeasts, and endemic 
mycoses to be examined in the near future.21,23–29
Pharmacology
Isavuconazonium is a prodrug of isavuconazole and 
is a water-soluble molecule consisting of a N-(3-
acetoxypropyl)-N-methylamino-carboxymethyl group 
attached to isavuconazole via an ester moiety (Figure 1).30 
Isavuconazonium sulfate is the commercially available 
prodrug formulation and is available in both an oral cap-
sule and IV lyophilized powder.9,31 The IV formulation of 
isavuconazonium sulfate is 372 mg, which is equivalent 
to 200 mg of isavuconazole. The oral capsule has 186 mg 
of isavuconazonium sulfate leading to 100 mg of isavu-
conazole.31 Special attention should be paid to initiation 
of this agent as dosing isavuconazonium sulfate involves 
a loading dose followed by once daily administration. The 
loading dose is 372 mg of isavuconazonium sulfate (200 mg 
of isavuconazole) every 8 hours for 2 days, then 372 mg of 
isavuconazonium sulfate (200 mg of isavuconazole) once 
daily. When transitioning from an IV to an oral formula-
tion, a repeat loading dose is not necessary.32 Dosing in 
the pediatric population has not been determined (trial is 
ongoing) and no recommendations can be given for this 
population.
Isavuconazonium’s oral formulation is well absorbed and 
has excellent bioavailability (98%). In preclinical studies 
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 isavuconazole exhibited linear and dose-proportional pharma-
cokinetics with low interpatient variability (2.5±1.0 µg/mL).33 
Food has no effect on the pharmacokinetics of isavuconazo-
nium and is not a limitation during its administration.31 The 
volume of distribution for isavuconazonium is large at 450 L 
and the drug half-life is 130 hours. Thus tissue levels persist 
long after plasma levels are undetectable.29
The IV prodrug formulation is water soluble, unlike vori-
conazole or posaconazole, and does not require cyclodextrin 
for solubilization. Following IV infusion, the prodrug and 
inactive cleavage product are undetectable after 30 minutes. 
With oral administration, the maximum concentration (C
max
) 
is reached within 2–3 hours; the prodrug and cleavage prod-
ucts are undetectable with oral administration. Elimination 
occurs primarily via the fecal route while renal excretion is 
,1% of the dose administered suggesting little utility in the 
treatment of fungal urinary tract infections.32,34
The metabolism of isavuconazonium is through rapid 
hydrolyzation, mainly by serum butylcholinesterase, to 
isavuconazole; CYP3A4, CYP3A5, and uridine diphosphate-
glucuronosyl transferase are substrates of isavuconazole.32 
The metabolites do not possess antifungal activity. In those 
with mild-to-moderate hepatic impairment (Child–Pugh 
class A or B) dosage adjustment is not needed. No data are 
available for dosing in those with Child–Pugh class C liver 
disease.
Renal impairment does not result in changes in the C
max
 or 
AUC of isavuconazole and dosage adjustment is not needed 
in this group either. Pharmacokinetic studies have not been 
performed in dialysis patients to date, however, it is likely not 
cleared by hemodialysis or continuous hemofiltration.8
Isavuconazole is a pregnancy class C drug and should 
not be administered to pregnant women. Additionally, it is 
present in breast milk and should not be given to women 
who are breastfeeding.
Drug–drug interactions
The triazole antifungal agents demonstrate significant 
drug–drug interactions that may adversely affect patient 
outcomes.35 Each patient’s current medications should be 
reviewed for potentially deleterious drug interactions. As a 
class, these include altered serum levels of the azoles and of 
coadministered agents including calcineurin inhibitors and 
mammalian target of rapamycin inhibitor immunosuppres-
sive agents, psychiatric and neurotropic medications, some 
benzodiazepines, digoxin, and antiretroviral agents among 
others.36–52 All of the azoles have important interactions via 
the CYP450 enzymes, notably CYP3A4.
Inhibitors of CYP3A4 lead to increased levels of isavu-
conazole and should be used with caution (Table 1). Inducers 
of CYP3A4 include rifampin, carbamazepine, barbiturates 
among others and significantly reduce serum levels of isavu-
conazole and concurrent administration should be avoided.
Isavuconazole is a moderate inhibitor of CYP3A4 
and impairs the metabolism of sirolimus, tacrolimus, and 
cyclosporine causing higher levels of these immunosuppres-
sive medications and warranting drug monitoring.53
TDM is routinely used for voriconazole, and in selected 
cases is used for fluconazole, itraconazole, and posaconazole.54 
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Figure 1 Metabolism of isavuconazonium by plasma esterases into an inactive 
byproduct and the active antifungal isavuconazole.
Table 1 effect of isavuconazole compared to voriconazole on 
CYP substrates
CYP Substrate Isavuconazole Voriconazole
3A4 Midazolam ↑2.05-fold ↑10.3-fold
Sirolimus ↑1.84-fold ↑11.0-fold
1A2 Caffeine NCS NCS
2C8 Repaglinide NCS NCS
2C9 warfarin NCS ↑2-fold (PT)
2C19 Omeprazole NCS ↑4-fold
2B6 Buproprion ↓42% ↑1.3-fold
2D6 Dextromethorphan NCS NCS
Abbreviations: CYP, cytochrome; NCS, not clinically significant; PT, prothrombin 
time.
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No recommendation can be made for or against routine isa-
vuconazole TDM, however, in some clinical cases it is clear 
TDM will be needed (eg, bidirectional drug–drug interac-
tions, during care of the morbidly obese).
Current treatments for invasive 
aspergillosis and mucormycosis
Both invasive aspergillosis and mucormycosis are devastating 
infections and improving patient outcomes requires aggres-
sive screening of at-risk populations to ensure early diagnosis 
and the rapid initiation of appropriate antifungal therapy. The 
currently recommended first-line therapy in the treatment of 
invasive aspergillosis is voriconazole,55 with amphotericin B 
formulations and echinocandins reserved for those intoler-
ant or refractory to this agent. The  Mucorales are treated by 
amphotericin B with adjunctive surgical intervention when 
possible, yet mortality remains between 50% and 100%.56 
Due to the aforementioned problems with currently available 
antifungal agents, isavuconazole was developed specifically 
to provide advantages over currently available antifungal 
compounds and has now been studied in three Phase III trials: 
1) the SECURE trial – isavuconazole versus voriconazole for 
primary treatment of invasive mold disease caused by Asper-
gillus and other filamentous fungi; 2) the VITAL trial – an 
open label study of isavuconazole in the treatment of patients 
with aspergillosis and renal impairment or of patients with 
invasive fungal disease caused by rare molds, yeasts, or 
dimorphic fungi; and 3) Isavuconazole (BAL8557) in the 
treatment of candidemia and other invasive Candida infec-
tions. Together these trials provide important information on 
the efficacy, safety, and clinical use of isavuconazole.
Clinical efficacy
The SECURE study was a Phase III, double-blind, random-
ized noninferiority study to compare the efficacy and safety 
of isavuconazole to voriconazole in the primary treatment 
of Aspergillus spp. or other filamentous fungi.57 The primary 
endpoint was all-cause mortality at day 42 in the intention-
to-treat (ITT) population. The main secondary endpoint 
was a composite of clinical, mycological, radiological, and 
overall response, as assessed by a blinded data-review com-
mittee (DRC). Patients randomized to isavuconazole were 
administered 200 mg IV three times a day for days 1 and 
2,  followed by either IV or oral 200 mg once daily. Those 
patients receiving voriconazole were administered 6 mg/
kg IV twice daily on day 1, followed by 4 mg/kg IV twice 
daily on day 2, then either 4 mg/kg IV twice daily or 200 
mg oral twice daily from day 3 onwards. Overall 516 adult 
patients were randomized and treated (258 per group) in the 
ITT population. The baseline demographics were similar 
between the two treatment groups, although there were fewer 
males in the isavuconazole group and more acute myeloid 
leukemia patients in the voriconazole group. All-cause 
mortality through day 42 for the ITT population was 18.6% 
(isavuconazole) and 20.2% (voriconazole; adjusted treatment 
difference: –1.0%; 95% confidence interval: −7.8%, 5.7%). 
Overall response rates at end of treatment in the modified 
ITT population were 35.0% (isavuconazole) and 36.4% 
(voriconazole). The study concluded that isavuconazole 
was noninferior to voriconazole for the primary treatment of 
invasive mold disease and the US Food and Drug Administra-
tion (FDA) and European  Medicines Agency (EMA) have 
since licensed isavuconazole for the treatment of invasive 
aspergillosis.
The VITAL study was a Phase III, open-label, noncompar-
ative trial evaluating the efficacy and safety of isavuconazole 
in patients with invasive aspergillosis with renal impairment 
or as primary or salvage treatment for  mucormycosis.58 
 Isavuconazole 200 mg (IV or oral) was given three times 
daily for six doses, followed by 200 mg/day until invasive 
fungal disease resolution or $180 days. Outcomes included 
mortality at day 42 and overall response as determined by 
an independent DRC. Of the 149 patients enrolled, 37 had 
proven (86%) or probable (14%) invasive mucormycosis 
by European Organization for Research and Treatment of 
Cancer/Mycoses Study Group criteria.59 Mortality at day 42 
was 37.8%. A matched case-control cohort of 33 patients 
treated with amphotericin B from the FungiScope registry 
was compared with 21 patients who received isavuconazole 
for the primary treatment of mucormycosis. Mortality rates 
were not significantly different between cases and controls 
(33.3% and 41.3%, respectively). A relationship between 
trough isavuconazole levels, fungal isolate MICs, and key 
outcomes could not be identified, possibly due to the rela-
tively small number of patients with data available. Clinical 
responses occurred across the range of isavuconazole MICs 
and trough levels observed. The FDA has licensed isavucon-
azole for the treatment of mucormycosis, while the EMA 
has licensed  isavuconazole in those for whom amphotericin 
B  formulations are inappropriate. This difference suggests 
the continued opinion that amphotericin B formulations are 
first-line therapy for most cases of mucormycosis.
Safety and tolerability
Isavuconazole has been shown to be fairly well toler-
ated and safe thus far. In the SECURE study, patients on 
isavuconazole had significantly fewer study drug-related 
adverse events (AEs), as compared to voriconazole (42.4% 
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vs 59.8%; P,0.001). AEs frequently associated with 
voriconazole such as visual disturbances, elevation in 
hepatic enzymes, and photosensitivity were significantly 
less common with isavuconazole. A few less frequent side 
effects noted were hypokalemia, peripheral edema, and 
infusion-related reactions. Acute respiratory distress, chills, 
dyspnea, and hypotension were among the infusion-related 
reactions.
Similar AE results were shown in the VITAL study. In 
total, 35/37 (95%) patients experienced one or more AEs 
during treatment, and 28 (76%) patients had serious AEs. 
The most common AEs were gastrointestinal complaints, 
such as nausea, vomiting, and diarrhea. Twenty-four patients 
discontinued isavuconazole treatment in the VITAL study, of 
which, six of these patients stopped due to AEs (relapse or 
progression of malignancy, two patients; acute liver injury, 
two patients; Escherichia coli bacteremia, one patient; 
and nausea, one patient). Overall, the AEs reported in the 
VITAL trial were similar in distribution to those reported 
in the SECURE invasive aspergillosis trial. There was no 
organ-specific pattern of serious AEs, however, as with all 
other azoles, liver enzymes should be monitored in patients 
receiving isavuconazole.
Isavuconazole differs uniquely from other triazoles in its 
class, in that it has dose- and concentration-dependent QTc 
interval shortening.7 QTc shortening up to 13 ms with 200 
mg once daily dosing and 24.6 ms with 600 mg daily have 
been shown in healthy volunteers. Inhibition of the L-type 
calcium channel is the proposed mechanism by which QTc 
shortening occurs.31 The clinical significance of this effect 
is unclear, however, those with familial short-QT syndrome 
should not receive isavuconazole.
Patient-focused perspectives
There are several advantages of isavuconazole, inherent in its 
pharmacology, which lend itself well to patient convenience 
and adherence. Unlike posaconazole and itraconazole, isa-
vuconazole absorption is not affected by food and exhibits 
excellent oral bioavailability, close to 98%.7 These aspects 
lend themselves well for easy IV-to-PO conversion once 
a patient is clinically stable. Additionally, thus far there 
has been little interpatient variability suggesting routine 
TDM may not be necessary, however, further study in this 
area is needed before any recommendation for or against 
TDM can be made. The dosing of isavuconazole after the 
48-hour loading period is once daily, with two capsules 
of 186 mg isavuconazonium sulfate taken daily adding in 
patient  convenience and potentially compliance. The IV 
formulation of isavuconazole does not require solubilization 
from a cyclodextrin vehicle, which eliminates concerns of 
nephrotoxicity that have arisen from the solubilizing agent 
including with IV voriconazole.60,61
The reduction in side effects in the isavuconazole 
treated patients compared to voriconazole treated patients 
in the SECURE study (difference of 17%) does provide a 
significant advantage. Side effects of therapy may prolong 
hospital stays, delay additional chemotherapy while medica-
tion changes are made or patient symptoms resolve, and/or 
lead to patient distress (particularly visual hallucinations). 
The reduction in these untoward events, while maintaining 
antifungal efficacy, is a welcome additional to the antifungal 
armamentarium.
Long-term therapy with voriconazole has been linked 
with cutaneous malignancy,62–64 and hyperfluorosis with the 
development of painful exostoses in patients with impaired 
renal function.65,66 The side effects of isavuconazole with 
long-term use have not been fully evaluated, however,  several 
patients in the VITAL study received prolonged therapy 
without side effects. Cutaneous malignancy has not been 
recognized to date, and hyperfluorosis with isavuconazole is 
unlikely given the differences in chemical structure between 
voriconazole and isavuconazole and that this phenomenon 
does not appear to be a class-effect.67
Conclusion
Isavuconazole has been recently approved by the FDA and 
EMA for the treatment of invasive aspergillosis and mucormy-
cosis. This new triazole offers several advantages over existing 
antifungals including comparable efficacy to currently used 
agents with fewer side effects, advantageous pharmacokinetic 
parameters, and excellent bioavailability with oral adminis-
tration. Future studies examining the role of isavuconazole 
in prophylaxis against invasive fungal infections, use in 
combination with other agents, and if TDM is necessary on 
a routine basis will further refine its role in the fight against 
these highly morbid and often lethal infections.
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